Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2004 Oct 25;167(2):223–229. doi: 10.1083/jcb.200408130

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2004, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 3. — Gene-targeted deletion of individual Src kinases protects against tumor cell extravasation. (A–C) Tumor burden, computed as the increase in lung/heart weight ratio over that for normal mice, was measured 12 d after i.v. inoculation with metastatic tumor cells. Mice lacking Src (A) or Yes (B and C) are protected from experimental pulmonary metastasis of CT26 (A and B) or D121 (C) cells. (D) This phenomenon is not specific to the lung, because Yes-deficient mice are also protected from experimental hepatic metastasis of CT26 or D121 cells. (E) Growth of primary tumors on the flank is not different between genotypes for CT26 or D121 cells. (F) Mice lacking Fyn, which show a normal vascular permeability response to VEGF, are not protected from metastasis. * indicates P < 0.05; n = 8 each bar. Bar, 1 mm.